Condition Lookup

Hypercholesterolemia

Specialty: Diabetes and Endocrinology

Sub-category: Dyslipidemia

Symptoms:
often asymptomatic; in severe cases, symptoms include xanthomas, xanthelasma (yellow deposits around the eyes), and corneal arcus.

Root Cause:
Elevated levels of low-density lipoprotein (LDL) cholesterol due to genetic or lifestyle factors, leading to an increased risk of atherosclerosis.

How it's Diagnosed: videos
Blood tests measuring LDL, HDL, total cholesterol, and triglycerides; clinical evaluation and family history.

Treatment:
Lifestyle modifications (diet, exercise, weight management), and medications to lower LDL cholesterol.

Medications:
Statins (e.g., atorvastatin , simvastatin ) are the first-line treatment to lower LDL cholesterol. Other options include bile acid sequestrants (e.g., cholestyramine ), cholesterol absorption inhibitors (e.g., ezetimibe ), and PCSK9 inhibitors (e.g., alirocumab ). Niacin and fibrates may be used in specific cases.

Prevalence: How common the health condition is within a specific population.
Approximately 12% of adults in the U.S. have elevated LDL cholesterol.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Poor diet (high in saturated and trans fats), obesity, sedentary lifestyle, smoking, excessive alcohol consumption, genetic predisposition (e.g., familial hypercholesterolemia).

Prognosis: The expected outcome or course of the condition over time.
Treatable with lifestyle changes and medications; untreated, it significantly increases the risk of cardiovascular disease, including heart attack and stroke.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Atherosclerosis, coronary artery disease, peripheral artery disease, and increased risk of myocardial infarction and stroke.

Hypertriglyceridemia

Specialty: Diabetes and Endocrinology

Category: Metabolic Disorders

Sub-category: Dyslipidemia

Symptoms:
often asymptomatic; severe cases may present with eruptive xanthomas, lipemia retinalis, or pancreatitis.

Root Cause:
Elevated triglyceride levels in the blood, often due to lifestyle factors, obesity, diabetes, or genetic disorders.

How it's Diagnosed: videos
Blood tests measuring fasting triglycerides; additional tests to identify secondary causes or genetic predispositions.

Treatment:
Lifestyle changes (low-fat, low-sugar diet, regular exercise, weight loss, avoiding alcohol) and triglyceride-lowering medications.

Medications:
Fibrates (e.g., fenofibrate , gemfibrozil ) are the primary treatment. Omega-3 fatty acids (e.g., prescription-strength EPA/DHA) and niacin can also lower triglycerides . Statins may be used when LDL is elevated.

Prevalence: How common the health condition is within a specific population.
Approximately 25% of adults in the U.S. have elevated triglycerides.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Obesity, diabetes, metabolic syndrome, excessive alcohol intake, high-carbohydrate diet, certain medications (e.g., corticosteroids).

Prognosis: The expected outcome or course of the condition over time.
Treatable with lifestyle changes and medications; untreated, severe hypertriglyceridemia can lead to pancreatitis and cardiovascular complications.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Acute pancreatitis, cardiovascular disease, and metabolic syndrome.

Mixed Hyperlipidemia

Specialty: Diabetes and Endocrinology

Category: Metabolic Disorders

Sub-category: Dyslipidemia

Symptoms:
usually asymptomatic; may present with xanthomas or cardiovascular events if untreated.

Root Cause:
Concurrent elevation of LDL cholesterol, triglycerides, and often low HDL cholesterol; typically caused by genetic factors or metabolic disorders.

How it's Diagnosed: videos
Blood lipid panel showing elevated LDL, triglycerides, and low HDL; clinical history and genetic testing may be needed.

Treatment:
Combination of lifestyle changes and medications targeting both LDL and triglycerides.

Medications:
Statins (e.g., atorvastatin , rosuvastatin ) are often combined with fibrates (e.g., fenofibrate ) or omega-3 fatty acids. Ezetimibe and PCSK9 inhibitors may be considered in severe cases.

Prevalence: How common the health condition is within a specific population.
Mixed hyperlipidemia affects 1%-5% of the population and is often associated with metabolic syndrome.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of dyslipidemia, obesity, diabetes, sedentary lifestyle, high-fat diet.

Prognosis: The expected outcome or course of the condition over time.
Treatable but requires consistent management to reduce cardiovascular risk; progression to cardiovascular disease if untreated.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Atherosclerosis, coronary artery disease, stroke, and pancreatitis.

Familial Hypercholesterolemia (FH)

Specialty: Diabetes and Endocrinology

Category: Metabolic Disorders

Sub-category: Dyslipidemia

Symptoms:
tendon xanthomas; xanthelasma; early corneal arcus; premature cardiovascular disease (e.g., heart attacks in young adults)

Root Cause:
Genetic mutations in LDL receptor, apolipoprotein B, or PCSK9 result in reduced clearance of LDL cholesterol from the blood.

How it's Diagnosed: videos
Blood lipid profile showing very high LDL cholesterol levels, genetic testing for mutations, and family history of premature cardiovascular disease.

Treatment:
Aggressive LDL-lowering therapy, including medications and sometimes LDL apheresis. Lifestyle changes are supportive.

Medications:
High-intensity statins (e.g., atorvastatin , rosuvastatin ) are first-line. PCSK9 inhibitors (e.g., evolocumab , alirocumab ) are often added. Ezetimibe and bile acid sequestrants may also be used. LDL apheresis may be required in severe cases.

Prevalence: How common the health condition is within a specific population.
Affects 1 in 250 individuals worldwide; homozygous FH is rarer, occurring in 1 in 1 million people.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Inherited autosomal dominant condition; risk factors exacerbate outcomes, including poor diet, smoking, and sedentary lifestyle.

Prognosis: The expected outcome or course of the condition over time.
Without treatment, most individuals develop cardiovascular disease by their 30s-40s (heterozygous) or even earlier (homozygous). With treatment, prognosis improves significantly.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Severe atherosclerosis, early-onset coronary artery disease, myocardial infarction, stroke, and aortic stenosis.

Obesity (Endocrine-Related)

Specialty: Diabetes and Endocrinology

Category: Metabolic Disorders

Sub-category: Obesity and Metabolic Syndrome

Symptoms:
excessive body fat; difficulty losing weight; fatigue; shortness of breath; joint pain; snoring or sleep apnea; insulin resistance

Root Cause:
Chronic imbalance between calorie intake and energy expenditure influenced by genetic, hormonal, and environmental factors, including abnormalities in the hypothalamic-pituitary axis, leptin resistance, and insulin dysregulation.

How it's Diagnosed: videos
Diagnosis is based on BMI ≥30 kg/m², waist circumference, body fat percentage, and associated comorbidities (e.g., type 2 diabetes, hypertension). Blood tests may assess insulin resistance, lipid profile, thyroid function, and cortisol levels.

Treatment:
Lifestyle interventions (diet and exercise), behavior modification programs, pharmacotherapy, and bariatric surgery for severe cases. Treatment plans are personalized based on comorbid conditions and underlying factors.

Medications:
Medications prescribed for obesity include orlistat (lipase inhibitor), liraglutide (GLP-1 receptor agonist), and semaglutide (GLP-1 receptor agonist). Other options may include phentermine-topiramate (appetite suppressant) or naltrexone-bupropion (combination therapy for appetite and reward system modulation).

Prevalence: How common the health condition is within a specific population.
Over 1 billion adults worldwide are affected; the prevalence is rising globally due to sedentary lifestyles and high-calorie diets.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Genetic predisposition, sedentary lifestyle, high-calorie diet, hormonal disorders (e.g., hypothyroidism, Cushing's syndrome), certain medications (e.g., antipsychotics, corticosteroids), and socioeconomic factors.

Prognosis: The expected outcome or course of the condition over time.
With appropriate intervention, weight loss and risk reduction for comorbid conditions are achievable. Long-term success depends on adherence to lifestyle and treatment plans.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Type 2 diabetes, cardiovascular disease, hypertension, sleep apnea, osteoarthritis, non-alcoholic fatty liver disease (NAFLD), certain cancers, and reduced life expectancy.

Hyperuricemia and Gout (Endocrine-Related)

Specialty: Diabetes and Endocrinology

Category: Metabolic Disorders

Sub-category: Other Metabolic Conditions

Symptoms:
severe joint pain, often in the big toe; redness and swelling of affected joints; warmth and tenderness in joints; limited range of motion; tophi (deposits of uric acid crystals) in chronic cases

Root Cause:
Excess uric acid in the blood due to overproduction or underexcretion of uric acid, often associated with metabolic dysfunctions. Uric acid crystals deposit in joints and tissues, causing inflammation and pain.

How it's Diagnosed: videos
Diagnosis includes blood tests to measure uric acid levels, synovial fluid analysis to identify uric acid crystals, and imaging (X-ray, ultrasound, or dual-energy CT) to detect crystal deposits.

Treatment:
Lifestyle changes such as dietary modifications (low-purine diet), weight loss, and limiting alcohol intake; medications for acute attacks and long-term management.

Medications:
Medications include nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen for pain, colchicine for acute attacks, and corticosteroids for severe inflammation. Long-term management may involve uricosuric agents like probenecid to increase uric acid excretion or xanthine oxidase inhibitors like allopurinol and febuxostat to reduce uric acid production.

Prevalence: How common the health condition is within a specific population.
Affects about 4% of adults globally, more common in men and postmenopausal women.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, obesity, high-purine diet, excessive alcohol consumption, certain medications (e.g., diuretics), chronic kidney disease, and metabolic syndrome.

Prognosis: The expected outcome or course of the condition over time.
With proper management, acute attacks can be controlled, and long-term complications prevented. However, untreated hyperuricemia may lead to chronic gout, joint damage, and kidney stones.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Chronic gout, joint deformities, kidney stones, and uric acid nephropathy.

Lipodystrophy (Abnormal Fat Distribution)

Specialty: Diabetes and Endocrinology

Category: Metabolic Disorders

Sub-category: Other Metabolic Conditions

Symptoms:
loss of subcutaneous fat in some areas; accumulation of fat in other areas (e.g., face, neck, abdomen); insulin resistance; high triglycerides; muscle hypertrophy in affected areas; leptin deficiency symptoms like excessive hunger and metabolic dysfunction

Root Cause:
A disorder in fat metabolism resulting in abnormal fat distribution, caused by genetic mutations, autoimmune conditions, or certain medications (e.g., antiretroviral therapy). This affects adipose tissue function, leading to insulin resistance and metabolic complications.

How it's Diagnosed: videos
Physical examination, blood tests (lipid profile, insulin resistance markers, leptin levels), genetic testing for hereditary forms, and imaging studies like MRI or CT for fat distribution analysis.

Treatment:
Lifestyle interventions like diet and exercise; leptin replacement therapy (metreleptin) for leptin-deficient cases; treatment of metabolic complications (e.g., diabetes, dyslipidemia) with medications.

Medications:
Metreleptin , a leptin analog, is used for leptin deficiency. Insulin sensitizers like metformin and thiazolidinediones can improve insulin resistance. Statins or fibrates manage dyslipidemia. Omega-3 fatty acids are used for hypertriglyceridemia.

Prevalence: How common the health condition is within a specific population.
Rare, with an estimated prevalence of 1-4 cases per million people; more common in women for some forms.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Genetic predisposition, autoimmune disorders, prolonged use of certain medications (e.g., HIV antiretroviral therapy).

Prognosis: The expected outcome or course of the condition over time.
Management can mitigate metabolic complications, but patients require lifelong monitoring. Prognosis depends on the severity of associated metabolic issues.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Severe insulin resistance, diabetes, cardiovascular disease, pancreatitis from hypertriglyceridemia, and liver steatosis or cirrhosis.